SEC Form 4 · accession 0001209191-17-047197
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred D Kingsley
Officer — See Remarks · Director
Period of report
Jul 31, 2017
Accepted (ET)
Aug 2, 2017 · 6:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par valueF1,F2 | Jul 31, 2017 | S | 150,000 | $2.80 | D | 5,781,555 | D | |
| Common Shares, no par value | holding | — | — | — | 1,143,346 | I | By Greenbelt Corp. | |
| Common Shares, no par value | holding | — | — | — | 375,351 | I | By Greenway Partners, LP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common SharesF3 | $3.15 | holding | — | — | — | — | Jun 30, 2022 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF4 | $2.72 | holding | — | — | — | — | Jun 30, 2021 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF5 | $3.57 | holding | — | — | — | — | Jun 30, 2020 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF6 | $3.11 | holding | — | — | — | — | Jun 30, 2019 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF7 | $4.13 | holding | — | — | — | — | Jun 30, 2018 | Common Shares | 50,000 | 50,000 | D |
Explanation of responses
- F1The securities were sold in a private transaction. Substantially all of the sale proceeds were invested in AgeX Therapeutics, Inc., a new subsidiary of BioTime.
- F2Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
- F3Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors.
- F4Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.
- F5Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.
- F6Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.
- F7Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013.
Remarks
Mr. Kingsley is Chairman of certain BioTime subsidiaries.